Novartis Raises Kesimpta Sales Potential To $8 Billion And Extends Its Growth Outlook
The drugmaker also lifted forecasts for Scemblix and Leqvio as it looks to grow through patent losses and trial setbacks.
Novartis, a Swiss medicines company, raised its peak-sales forecast for Kesimpta to $8 billion from $6 billion on Thursday. It also extended its outlook by a year, projecting 5% average annual net-sales growth in constant currencies for 2026-2031 in its announcement furnished to the U.S. Securities and Exchange Commission.
Marketed Medicines Carry The Forecast
Novartis lifted peak-sales expectations for Scemblix and Leqvio to $5 billion apiece, from $4 billion each. These forecasts describe the medicines' potential sales at their peak, rather than revenue expected in a particular year.
Vas Narasimhan, Novartis's chief executive, attributed the increases mainly to commercial performance. He cited market-share gains for Kesimpta and Scemblix, and strong demand for Leqvio in the U.S. and Asia.
The company recently raised Rhapsido/remibrutinib's peak-sales outlook to $8 billion across chronic spontaneous urticaria, chronic inducible urticaria and relapsing multiple sclerosis. It sees additional multibillion-dollar potential in other uses.
Novartis now assigns peak-sales potential of $3 billion to $10 billion to nine marketed assets: Kisqali, Rhapsido, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, Fabhalta and the Zolgensma Group, which includes Zolgensma and Itvisma.
The portfolio spans medicines for cancer, neurological conditions and inflammatory diseases. Kesimpta treats multiple sclerosis, Kisqali treats breast cancer and Cosentyx treats psoriasis and other inflammatory conditions. Novartis sells products in approximately 120 countries, principally generating sales in the U.S. and Europe.
Patent Losses And September Setbacks
Novartis expects U.S. generic competition for Kisqali in the second half of 2031. Narasimhan said that timing helped shape the extended sales outlook, which excludes exchange-rate effects.
Narasimhan said Novartis expects to grow through “the largest loss-of-exclusivity impact in our history” in 2026 — the loss of protections that keep competing versions of medicines off the market. The company still expects its core operating income margin to return above 40% by 2029.
The growth plan follows disappointments in experimental medicines. Novartis bought Avidity Biosciences earlier this year for $12 billion, gaining experimental drug del-desiran in the deal.
In September, the pelacarsen cardiovascular trial failed to show improved cardiovascular outcomes. The next day, del-desiran failed a late-stage trial. Novartis shares fell nearly 11% following that failure, their biggest single-day decline since 1987.
More Than 35 Trial Readouts
Novartis expects more than 35 trial readouts through 2031 that could support regulatory submissions. It has more than 30 potentially high-value development assets, including 10 late-stage assets with multibillion-dollar peak-sales forecasts.
More than 20 assets are in registration, late-stage or mid-stage development; more than 10 are in or entering early-stage trials. Management expects the pipeline to help sustain annual sales growth of about 5% over the longer term.
The programs span cardiovascular, renal and metabolic disease, immunology, neuroscience and oncology. Examples include abelacimab for stroke prevention in atrial fibrillation, ianalumab for systemic lupus erythematosus, votoplam for Huntington's disease and pelabresib for myelofibrosis.
Novartis is featuring the outlook at its Meet Novartis Management event in London. Narasimhan's planned update includes the company's use of artificial intelligence in research, development, manufacturing and commercial operations.
Narasimhan is scheduled to appear on CNBC TV at 11 a.m. ET Thursday.
Sources
- Form 6-K — Novartis International AG CH-4002 Basel Switzerland https://www.novartis.com https://x.com/novartisnews PRESS RELEASE Novartis projects +5% cc 1 sales CAGR through 2031 and sustained mid-si — SEC EDGAR
- Novartis raises peak sales forecast for three drugs to $18 billion — CNBC